Intravacc is developing several innovative proprietary vaccines under the name Avacc. Each vaccine candidate is based on one of our platform technologies and the products are in various stages of development.
All of our products are available for licensing or partnering. If you are interested, our team is happy to discuss all possibilities with you.
A first-in-class prophylactic quadrivalent vaccine against hand, foot, and mouth disease (HFMD).
Intravacc’s vaccine candidate against Pertussis, based on our proprietary OMV based platform.
A first-in-class inactivated-virus vaccine against enterovirus D68.
An intranasal vaccine against COVID-19 based on Neisseria meningitidis Outer Membrane Vesicles mixed with stabilized spike protein.
A first-in-class vaccine against gonorrhea based on Neisseria gonorrhoeae outer membrane vesicles and encapsulated IL-12.
A vaccine against gonorrhea based on Neisseria meningitidis Outer Membrane Vesicles expressing N. gonorrhoeae antigens.
An outer membrane vesicle vaccine protecting against Neisseria meningitidis serogroup B.
A peptide-based conjugate vaccine targeting a neurotoxic dipeptide repeat protein found in patients with C9orf72 amyotrophic lateral sclerosis (C9-ALS).
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
